GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starton Therapeutics Inc (NAS:STA) » Definitions » Minority Interest

Starton Therapeutics (Starton Therapeutics) Minority Interest : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2050. Start your Free Trial

What is Starton Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Starton Therapeutics's minority interest for the quarter that ended in Jun. 2023 was $0.00 Mil.


Starton Therapeutics Minority Interest Historical Data

The historical data trend for Starton Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starton Therapeutics Minority Interest Chart

Starton Therapeutics Annual Data
Trend Mar21 Mar22 Mar23
Minority Interest
- - -

Starton Therapeutics Quarterly Data
Mar21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23
Minority Interest Get a 7-Day Free Trial - - - - -

Starton Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Starton Therapeutics (Starton Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
215 College Road, Suite No.300, Paramus, NJ, USA, 07652
Starton Therapeutics Inc is a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer can receive continuous treatment to live better, and longer. Starton's proprietary continuous delivery technology can increase the efficacy of approved drugs, make them more tolerable, and expand their potential use.

Starton Therapeutics (Starton Therapeutics) Headlines

No Headlines